Intra-patient heterogeneity in urothelial cancer (UC) circulating tumor cells (CTC) and PDL1 expression to identify biomarkers of response and new therapeutic targets: A pilot study.
Waddah Arafat(Southwestern Medical Center), Petros Grivas(Seattle Cancer Care Alliance), Brian I. Rini(Vanderbilt University Medical Center), Moshe Chaim Ornstein(Cleveland Clinic), Erika Héninger(University of Wisconsin Carbone Cancer Center), Nita Hoxha(Cleveland Clinic), Pam Profusek(Cleveland Clinic), Dharmesh Gopalakrishnan(Roswell Park Comprehensive Cancer Center), Pedro C. Barata(University Hospitals Seidman Cancer Center), Jamie M. Sperger(University of Wisconsin–Madison), Christos E. Kyriakopoulos(Dana-Farber Cancer Institute), Charlotte N. Stahlfeld(University of Wisconsin–Madison), Sarah Devonshire(Cleveland Clinic), Joshua M. Lang(University of Wisconsin–Madison), Jorge A. García(Cleveland Clinic), Marcelo Lamenza(Cleveland Clinic)
Cited by 5
Related Papers
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k